Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study

被引：0
|
作者：
JI Aróstegui
J Anton
I Calvo
A Robles
A Speziale
Y Joubert
G Junge
J Yagüe
机构：
[1] Hospital Clinic,
[2] Hospital Sant Joan de Déu,undefined
[3] Hospital La Fe,undefined
[4] Hospital La Paz,undefined
[5] Novartis Pharma AG,undefined
[6] Hospital Clinic,undefined
来源：
Pediatric Rheumatology | / 13卷 / Suppl 1期
关键词：
Withdrawal Period; Canakinumab; Periodic Fever Syndrome; Global Assessment Score; HIDS Patient;
D O I：
10.1186/1546-0096-13-S1-O58
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Long-term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
    Ignacio Arostegui, Juan
    Anton, Jordi
    Calvo-Penedes, Inmaculada
    Robles, Angel
    Speziale, Antonio
    Joubert, Yolandi
    Lunge, Guido
    Yague, Jordi
    PEDIATRICS, 2018, 141
  • [32] Long-Term Efficacy and Safety of Canakinumab in Active Hyperimmunoglobulinemia D with Periodic Fever Syndrome
    Ignacio Arostegui, Juan
    Anton, Jordi
    Calvo-Penedes, Inmaculada
    Robles, Angel
    Speziale, Antonio
    Joubert, Yolandi
    Junge, Guido
    Yaguee, Jordi
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [33] Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome)results from the European phase 3 open-label safety trial
    Tack, J.
    Pokrotnieks, J.
    Urbonas, G.
    Banciu, C.
    Yakusevich, V.
    Bunganic, I.
    Tornblom, H.
    Kleban, Y.
    Eavis, P.
    Tsuchikawa, M.
    Miyagawa, T.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2018, 30 (06):
  • [34] Long-term efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: Results of an open-label, 2-year trial
    Haibel, H.
    Brandt, H. C.
    Baraliakos, X.
    Rudwaleit, M.
    Listing, J.
    Braun, J.
    Kupper, H.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 218 - 219
  • [35] Maintenance of long-term efficacy and safety of quetiapine in the open-label treatment of schizophrenia
    Kasper, S
    Brecher, M
    Fitton, L
    Jones, AM
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (05) : 281 - 289
  • [36] Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial
    Grossman, J
    Smith, LJ
    Wilson, AM
    Thyrum, PT
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 1999, 82 (04) : 361 - 369
  • [37] Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
    Thompson, William R.
    Manuel, Ryan
    Abbruscato, Anthony
    Carr, Jim
    Campbell, John
    Hornby, Brittany
    Vaz, Frederic M.
    Vernon, Hilary J.
    GENETICS IN MEDICINE, 2024, 26 (07)
  • [38] Trofinetide for the treatment of Rett syndrome Long-term safety and efficacy results of the 32-month, open-label LILAC-2 study
    Percy, Alan K.
    Neul, Jeffrey L.
    Benke, Timothy A.
    Berry-Kravis, Elizabeth M.
    Glaze, Daniel G.
    Marsh, Eric D.
    Barrett, Amy M.
    An, Di
    Bishop, Kathie M.
    Youakim, James M.
    MED, 2024, 5 (10):
  • [39] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [40] Long-Term Efficacy and Safety of Deutetrabenazine for Chorea in Huntington's Disease: Results From the ARC-HD Open-Label Study
    Frank, Samuel
    Testa, Claudia M.
    Stamler, David
    Kayson, Elise
    Oakes, David
    Vaughan, Christina
    Goldstein, Jody
    Whaley, Jacquelyn
    Davis, Matthew D.
    Gordon, Mark Forrest
    Savolay, Juha-Matti
    NEUROTHERAPEUTICS, 2020, 17 (SUPPL 1) : 27 - 28
12345